Aberdeen group reports 6.33% stake in ProQR

Aberdeen Group plc and its affiliate abrdn Inc. report beneficial ownership of 8,932,507 Ordinary Shares of ProQR Therapeutics N.V., representing 6.33% of this class of shares.

Accepted by SEC EDGAR 07/29/2026 - 09:48 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Aberdeen Group plc and its affiliate abrdn Inc. report beneficial ownership of 8,932,507 Ordinary Shares of ProQR Therapeutics N.V., representing 6.33% of this class of shares. The securities are Ordinary Shares with a nominal value of EUR0.04 per share.

Both Aberdeen Group plc and abrdn Inc. report no sole voting or dispositive power over these shares, but each reports shared voting power and shared dispositive power over 8,932,507 shares. abrdn Inc. beneficially owns the shares on behalf of underlying clients within its corporate group structure.

Key Figures

Beneficially owned shares: 8,932,507 shares Percent of class: 6.33% Shared voting power: 8,932,507 shares +3 more

6 metrics

Beneficially owned shares 8,932,507 shares Ordinary Shares of ProQR Therapeutics N.V. reported by Aberdeen Group plc and abrdn Inc.

Percent of class 6.33% Percentage of ProQR Therapeutics Ordinary Shares beneficially owned

Shared voting power 8,932,507 shares Shares over which Aberdeen Group plc and abrdn Inc. share voting power

Shared dispositive power 8,932,507 shares Shares over which Aberdeen Group plc and abrdn Inc. share dispositive power

Nominal value per share EUR0.04 per share Nominal value of ProQR Therapeutics Ordinary Shares

Signature date 07/29/2026 Date Romiza Chaudhry signed as Major Shareholding Reporting Analyst

Key Terms

beneficially owns, shared voting power, shared dispositive power, parent holding company, +1 more

5 terms

beneficially owns financial

"abrdn Inc. beneficially owns on behalf of our underlying clients 5% or greater"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

shared voting power financial

"Shared Voting Power 8,932,507.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 8,932,507.00"

parent holding company financial

"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

Schedule 13G regulatory

"abrdn Inc. beneficially owns on behalf of our underlying clients 5% or greater of the outstanding shares of the security class being reported on this"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ProQR Therapeutics (PRQR) shares are beneficially owned by Aberdeen Group and abrdn Inc.?

Aberdeen Group plc and abrdn Inc. beneficially own 8,932,507 Ordinary Shares of ProQR Therapeutics N.V. This holding is reported on a Schedule 13G and reflects their aggregate beneficial ownership position.

What percentage of ProQR Therapeutics (PRQR) does Aberdeen Group and abrdn Inc. own?

Their reported beneficial ownership represents 6.33% of the outstanding Ordinary Shares of ProQR Therapeutics N.V. This percentage is calculated for the class of securities reported in the Schedule 13G filing.

Do Aberdeen Group and abrdn Inc. have sole or shared voting power over PRQR shares?

They report 0 shares with sole voting power and 8,932,507 shares with shared voting power. The same split applies to dispositive power, with authority held on a shared rather than sole basis.

Which entities in the abrdn group are involved in the ProQR (PRQR) ownership?

The ownership chain includes Aberdeen Group plc as parent, abrdn Holdings Limited as intermediate holding company, and abrdn Inc., which beneficially owns the shares on behalf of underlying clients.

What class of ProQR Therapeutics (PRQR) securities is reported in this Schedule 13G?

The filing covers Ordinary Shares of ProQR Therapeutics N.V. with a nominal value of EUR0.04 per share, identified by CUSIP N71542109 as disclosed in the ownership report.

Where are Aberdeen Group plc and abrdn Inc. based in relation to their PRQR holdings?

Aberdeen Group plc is based at 1 George Street, Edinburgh, United Kingdom EH2 2LL, while abrdn Inc. is based at 1900 Market Street, Suite 200, Philadelphia, PA 19103, reflecting their respective principal offices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ProQR Therapeutics NV

(Name of Issuer)

Ordinary Shares, nominal value EUR0.04 per share

(Title of Class of Securities)

N71542109

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): N71542109

1

Names of Reporting Persons

Aberdeen Group plc

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,932,507.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,932,507.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,932,507.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.33 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): N71542109

1

Names of Reporting Persons

abrdn Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,932,507.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,932,507.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,932,507.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.33 %

12

Type of Reporting Person (See Instructions)

CO, IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ProQR Therapeutics NV
(b)	Address of issuer's principal executive offices: Zernikedreef 9, Leiden, The Netherlands CK 2333
Item 2.
(a)	Name of person filing: Aberdeen Group plc abrdn Inc.
(b)	Address or principal business office or, if none, residence: Aberdeen Group plc: 1 George Street Edinburgh, United Kingdom EH2 2LL abrdn Inc.: 1900 Market Street, Suite 200 Philadelphia PA 19103
(c)	Citizenship: Aberdeen Group plc - UNITED KINGDOM abrdn Inc. - UNITED STATES
(d)	Title of class of securities: Ordinary Shares, nominal value EUR0.04 per share
(e)	CUSIP Number(s): N71542109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 8,932,507
(b)	Percent of class: 6.33 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Aberdeen Group plc - 0 abrdn Inc. - 0
	(ii) Shared power to vote or to direct the vote: Aberdeen Group plc - 8,932,507 abrdn Inc. - 8,932,507
	(iii) Sole power to dispose or to direct the disposition of: Aberdeen Group plc - 0 abrdn Inc. - 0
	(iv) Shared power to dispose or to direct the disposition of: Aberdeen Group plc - 8,932,507 abrdn Inc. - 8,932,507
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Aberdeen Group plc

Signature:	R. Chaudhry
Name/Title:	Romiza Chaudhry / Major Shareholding Reporting Analyst
Date:	07/29/2026

abrdn Inc.

Signature:	R. Chaudhry
Name/Title:	Romiza Chaudhry / Major Shareholding Reporting Analyst
Date:	07/29/2026

Exhibit Information

Aberdeen Group plc abrdn Holdings Limited abrdn Inc. Aberdeen Group plc is the parent company. abrdn Holdings Limited is the intermediate holding company for abrdn Inc. abrdn Inc. beneficially owns on behalf of our underlying clients 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G.